Advertisement
Document › Details
Eckert & Ziegler SE. (12/3/24). "Press Release: Eckert & Ziegler – Changes in the Executive Board and Supervisory Board". Berlin.
The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment.
Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head of development. He then served as managing director of various subsidiaries of Eckert & Ziegler SE and was appointed to the Group Executive Committee in 2011. Dr. Mann has proven expertise in the areas of radiation physics, process management and implementation of investment projects.
Jutta Ludwig, whose contract as a member of the Executive Board expires as planned on December 31, 2024 will join the Supervisory Board as a delegated member on January 1, 2025. Frank Perschmann will leave the Supervisory Board of Eckert & Ziegler SE at the end of the year.
“Dr. Mann knows Eckert & Ziegler like only few others and brings exactly the experience and expertise needed to expand production capacity in the growing medical segment and to set up facilities for new products,” explains Dr. Andreas Eckert, Chairman of the Supervisory Board of Eckert & Ziegler SE. “On behalf of the Supervisory Board, I would like to thank Mrs. Ludwig for her contribution in strengthening our position in China and I am pleased that her expertise will remain with the company. I would also like to express my thanks to Mr. Perschmann for his many years of work on the Supervisory Board and for his valuable input in the strategic development of the Group.”
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
Record changed: 2024-12-19 |
Advertisement
More documents for Eckert & Ziegler (Group)
- [1] Eckert & Ziegler SE. (12/5/24). "Press Release: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments". Berlin....
- [2] Eckert & Ziegler AG. (1/8/24). "Press Release: Eckert & Ziegler and ArtBio Announce Manufacturing and Supply Partnership for Lead-212 Conjugates". Berlin & Cambridge, MA....
- [3] Eckert & Ziegler AG. (11/14/23). "Press Release: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes". Berlin....
- [4] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
- [5] Eckert & Ziegler AG. (5/15/23). "Press Release: Reorganization in the Executive Board of Eckert & Ziegler". Berlin....
- [6] Eckert & Ziegler AG. (4/4/23). "Press Release: Eckert & Ziegler to Supply Point Biopharma with Actinium-225". Berlin & Indianapolis, IN....
- [7] Eckert & Ziegler Strahlen- und Medizintechnik AG. (12/19/22). "Press Release: Changes in the Management Board of Eckert & Ziegler. Insider Information Pursuant to Article 17 MAR". Cambridge....
- [8] Precirix N.V.. (9/12/22). "Press Release: Precirix Enters into Collaboration with Eckert & Ziegler for the Development of Its 68Ga-based Compounds". Brussels & Berlin....
- [9] Precirix N.V.. (7/26/22). "Press Release: Precirix and Eckert & Ziegler Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225". Brussels & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top